April 9, 2018

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., April 09, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement awards to its Senior Vice President and General Counsel, Mina Kim, effective as of April 9, 2018. Ms. Kim has nearly 20 years of corporate legal experience, most recently as the General Counsel of the publicly listed companies Sunrun Inc. and Fly Leasing Limited.

The compensation committee of Atara's board of directors granted Ms. Kim a stock option to purchase 70,000 shares of Atara’s common stock, and restricted stock units to acquire 42,500 shares of Atara’s common stock. The stock option and restricted stock units were granted as an inducement material to Ms. Kim entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option has a seven-year term and an exercise price of $36.00, equal to the per share closing price of Atara's common stock as reported by Nasdaq on April 9, 2018. The awards vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting over the following three years, assuming the employee is continuously employed by Atara as of such vesting dates.

Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (**@Atarabio**) is a leading T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The Company's off-the-shelf, or allogeneic, T-cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment. Atara's T-cell immunotherapies are designed to precisely recognize and eliminate cancerous or diseased cells without affecting normal, healthy cells.

INVESTOR & MEDIA CONTACTS:

Investors:
John Craighead, Atara Biotherapeutics
650-491-5806
jcraighead@atarabio.com

Steve Klass, Burns McClellan
212-213-0006 x331
sklass@burnsmc.com

Media:
Justin Jackson, Burns McClellan
212-213-0006 x327
jjackson@burnsmc.com

Primary Logo

Source: Atara Biotherapeutics, Inc.